Adial Pharmaceuticals delays shareholder meeting vote on proposals 3-6 to Oct. 15 pending Nasdaq approval
ADIL•Adial Pharmaceuticals postponed votes on four shareholder proposals until Oct. 15, 2026, pending Nasdaq approval of its initial listing application.
1. Vote postponed
The company adjourned its annual meeting, reconvened Oct. 1, with polls still open on proposals 3-6. The next session is scheduled for Oct. 15, 2026, at 8:30 a.m. ET at its Charlottesville, Virginia, offices. The Aug. 17, 2026, record date remains unchanged, and previously submitted proxies remain valid unless shareholders change their votes.
